Angiotensin converting enzyme inhibitor (ACE-i) or angiotensin II receptor blocker (ARB) medications are prescribed for conditions such as heart failure, high blood pressure or heart disease. They inhibit or block angiotensin, a chemical that causes arteries to become narrow, so are commonly prescribed for people with high blood pressure to relax and open blood vessels, lowering blood pressure.

They may also lower risk of colorectal cancer risk, the third most common cancer and second leading cause of cancer death worldwide.

Researchers reviewed health records of 187,897 adult patients in Hong Kong from 2005 to 2013, with a negative baseline colonoscopy for colorectal cancer. Since it is epidemiology, only exploratory, the retrospective study results should be verified with a prospective randomized controlled study, which would actively follow patients to determine the potential benefits of these medications on colorectal cancer risk. 



The analysis found that:

those who took hypertension medications such as ACE-i or ARBs had a 22% lower risk of developing colorectal cancer in the subsequent three years;

the benefits of ACE-i and ARBs were seen in patients 55 or older and those with a history of colon polyps; and

the benefit associated with the medications was limited to the first three years after the negative baseline colonoscopy.

"The roles of ACE inhibitors and ARBs on cancer development are controversial and, in some cases, study findings are conflicting. Results of previous studies have been limited by several factors including a small number of patients and data only on short-term follow-ups. Our results provide new insights on a potential role of these medications for colorectal cancer prevention," said study author Wai K. Leung, M.D., clinical professor of medicine at the University of Hong Kong in Hong Kong, China. "This is the first study to show the potential beneficial effects of ACE inhibitors and ARBs on colorectal cancer development, based on a large group of patients who were colorectal cancer-free at the beginning of the study."